Newsroom

Gruppenbild
News
Lipid-lowering drugs not a risk factor in COVID-19
Cholesterol-lowering drugs do not promote infection with the novel coronavirus SARS-CoV-2. This is the conclusion of a team of researchers from TWINCORE - Center for Experimental and Clinical Infection Research and the University of Veterinary Medicine Hannover Foundation, led by Prof Gisa Gerold, together with colleagues from the Helmholtz Centre for Infection Research (HZI) in Braunschweig and Umea University in Sweden. The scientists have studied several lipid-lowering agents from the group of statins in a cell culture model. They have now published their results in the journal iScience. The TWINCORE-Centre for Experimental and Clinical Infection Research is a joint institution of the Hannover MEdical School (MHH) and the HZI.
03.12.2021
HZI Campus
TWINCORE
Salmonellen
News
Key Virulence Factor of Salmonella characterized
Salmonella enterica, a foodborne pathogen, is one of four key global causes of diarrheal diseases, which affect over 550 million people each year. This rod-shaped, Gram-negative bacterium has tubular, whip-like appendages known as flagella that protrude from its surface. Researchers from the Centre for Structural Systems Biology (CSSB) in collaboration with researchers at Research Center Borstel FZB, as well as Max Plank Institute for Infection Biology, the University of Marburg and the Technische Universität Braunschweig studied biochemical and biophysical properties of these bacterial structures. Their study was recently published in PLoS Pathogens. The CSSB is a common initiative by ten northern German research institutions, including the Helmholtz Centre for Infection Research (HZI) in Braunschweig.
03.12.2021
CSSB
Group picture
Story
Results of the nationwide antibody study
From July 2020 to August 2021, a research team from the HZI, with external support, studied the antibody status of more than 26,000 people in seven county districts and thus collected important data on the pandemic event.
02.12.2021
HZI Campus
buch
Story
“There will be other, perhaps even more dangerous pandemics”
Though the Corona pandemic is not over yet, we should already start preparing for future pandemics. A look at what infection research can contribute.
02.12.2021
HZI Campus
HIOH
Immunfluoreszenz-Aufnahme der Lunge
News
COVID-19-related respiratory failure: Why patients require prolonged ventilation
30.11.2021
HIRI
Immunotherapy against hepatitis B
News
Who benefits from immunotherapy against hepatitis B?
Hepatitis B is a viral infection of the liver that can lead to cancer and organ failure. Antiviral therapies can suppress the infection, but a functional cure is rare. Novel immunotherapies may lead to an actual cure more often. However, it is still unclear which patients benefit most from these new therapies. Researchers at the Centre for Individualised Infection Medicine (CiiM), a joint institution of the Helmholtz Centre for Infection Research (HZI) and the Hannover Medical School (MHH), as well as the MHH and the German Center for Infection Research (DZIF), have now identified a biomarker that intends to enable predictions about the success of the therapy. The results were published in the scientific journal Gut.
25.11.2021
CiiM

HZI in the media

Mit Parkinson-Medikament zum Virulenzblocker gegen Krankenhauskeim

Quelle:

 

Pressemitteilung Helmholtz-Zentrum für Infektionsforschung HZI ...

10.12.2025
|
LaborPraxis
Parkinson-Medikament zeigt Wirkung gegen Krankenhauskeim: Saarbrücker Forschung entdeckt neuen Ansatz

Medikament Tolcapon identifiziert. Das HIPS ist ein Standort des Helmholtz-Zentrums für Infektionsforschung (HZI) in Kooperation ...

01.12.2025
|
Homburg
Kontinuität und frischer Wind: Neuer DZIF-Vorstand gewählt

... wissenschaftlicher Ko-Direktor des Helmholtz Zentrums für Infektionsforschung (HZI). Thomas Pietschmann engagiert sich seit 2023 im ...

28.11.2025
|
juraforum.de
Tolcapone & LecA: Blocking Bacterial Virulence Pathways

Dr. Alexander Titz, group leader at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS). “Finding new ways to disrupt its

28.11.2025
|
ARCHYDE
Kürzung von HIV-Programmen: Expertin warnt vor steigenden Fallzahlen

... “, sagte die Leiterin der Epidemiologie am Braunschweiger Helmholtz-Zentrum für Infektionsforschung.

 

Lange betonte, flächendeckende ...

28.11.2025
|
Evangelische Zeitung
Saarland: Saarland will Forschung stärker unterstützen und so Arbeitsplätze schaffen

... ein Zentrum für Quantentechnologie entstehen und das Helmholtz-Institut für Pharmazeutische Forschung ausgebaut werden.

 

Mehr ...

27.11.2025
|
Tagesschau
Barke: Halbe Milliarde Euro wird in Forschung investiert

Euro werden investiert in die Erweiterung des Helmholtz-Instituts für Pharmazeutische Forschung Saarland (HIPS). Und ...

27.11.2025
|
ZEIT online
Parkinson's drug tolcapone found to block key protein in hospital superbug

s drug tolcapone. HIPS is a site of the Helmholtz Center for Infection Research (HZI) in collaboration with Saarland University.

 

The

26.11.2025
|
Medical Xpress
„RNA Healer“ erhält rund eine Million Euro für Entwicklung von Leberfibrose-Therapie

... erhielt das Projekt „Citrapeutics“ vom Helmholtz-Zentrum für Infektionsforschung (HZI) in Braunschweig eine Förderung in Höhe ...

25.11.2025
|
Bionity.COM
Pattern of chronic rejection for liver transplants decoded

led by Hannover Medical School (MHH) and the Helmholtz Center for Infection Research (HZI) has now discovered clear molecular signatures for

24.11.2025
|
Medical Xpress
Lebertransplantation: Muster der chronischen Abstoßung entschlüsselt

Medizinischen Hochschule Hannover (MHH) und dem Helmholtz-Zentrum für Infektionsforschung (HZI), hat nun eindeutige molekulare Signaturen ...

24.11.2025
|
DeutschesGesundheitsPortal
HZI bringt Wissenschaft zum Anfassen in die Innenstadt

Braunschweig. Das Helmholtz-Zentrum für Infektionsforschung (HZI) bringt anlässlich seines 60. Jubiläums seine Forschung vom 3. ...

22.11.2025
|
Regional Heute

Register now for the HZI-Newsletter